Return to homepagePandemic Pact

SUPPLEMENTAL WORK-SARS-COV-2

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 272201800011C-P00007-9999-2

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $2,641,049

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    MICHAEL KAYTOR

  • Research Location

    United States of America

  • Lead Research Institution

    HUMANETICS CORPORATION

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The company will initiate a phase 2 trial to evaluate BIO 300 (oral, genistein antioxidant) to mitigate impaired pulmonary function in COVID-19 patients recently discharged from the hospital. COVID-19- and radiation-mediated lung damage share overlapping mechanisms of injury, and Humanetics already has BIO300 under study in the clinic to treat pneumonitis and pulmonary fibrosis in lung cancer patients receiving thoracic radiotherapy.